BACKGROUND: Inactivated influenza vaccines are manufactured using either split-virion or subunit methods. These 2 methods produce similar hemagglutinin antibody responses, but different cellular immune responses. METHODS: We compared the effectiveness of split-virion influenza vaccines to that of subunit influenza vaccines using prospectively collected data from adults aged ≥50 years who sought care for acute respiratory illness during 3 influenza seasons: 2008-2009, 2010-2011, and 2011-2012 using a case-positive, control test-negative study design. RESULTS: Complete data were available for 539 participants, of whom 68 (12.6%) had influenza detected. Influenza-infected patients were younger (P<.001), were more likely to have received no vaccine or the subunit influenza vaccine than the split-virion vaccine (P<.001), and more likely to have sought care in either the emergency department or the acute care clinic than the hospital (P=.001). Split-virion vaccine effectiveness was 77.8% (95% confidence interval [CI], 58.5%-90.3%) compared with subunit vaccine effectiveness of 44.2% (95% CI, -11.8% to 70.9%), giving a difference in vaccine effectiveness of 33.5% (95% CI, 6.9%-86.7%). CONCLUSIONS: Studies need to be done to further explore if there are differences in clinical effectiveness in older adults for the 2 vaccine manufacturing methods.
BACKGROUND: Inactivated influenza vaccines are manufactured using either split-virion or subunit methods. These 2 methods produce similar hemagglutinin antibody responses, but different cellular immune responses. METHODS: We compared the effectiveness of split-virion influenza vaccines to that of subunit influenza vaccines using prospectively collected data from adults aged ≥50 years who sought care for acute respiratory illness during 3 influenza seasons: 2008-2009, 2010-2011, and 2011-2012 using a case-positive, control test-negative study design. RESULTS: Complete data were available for 539 participants, of whom 68 (12.6%) had influenza detected. Influenza-infectedpatients were younger (P<.001), were more likely to have received no vaccine or the subunit influenza vaccine than the split-virion vaccine (P<.001), and more likely to have sought care in either the emergency department or the acute care clinic than the hospital (P=.001). Split-virion vaccine effectiveness was 77.8% (95% confidence interval [CI], 58.5%-90.3%) compared with subunit vaccine effectiveness of 44.2% (95% CI, -11.8% to 70.9%), giving a difference in vaccine effectiveness of 33.5% (95% CI, 6.9%-86.7%). CONCLUSIONS: Studies need to be done to further explore if there are differences in clinical effectiveness in older adults for the 2 vaccine manufacturing methods.
Authors: Donna M Murasko; Erica D Bernstein; Elizabeth M Gardner; Peter Gross; Gary Munk; Sandra Dran; Elias Abrutyn Journal: Exp Gerontol Date: 2002 Jan-Mar Impact factor: 4.032
Authors: Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu Journal: Nat Med Date: 2012-01-29 Impact factor: 53.440
Authors: H Keipp Talbot; Yuwei Zhu; Qingxia Chen; John V Williams; Mark G Thompson; Marie R Griffin Journal: Clin Infect Dis Date: 2013-02-28 Impact factor: 9.079
Authors: E Kissling; M Valenciano; U Buchholz; A Larrauri; J M Cohen; B Nunes; J Rogalska; D Pitigoi; I Paradowska-Stankiewicz; A Reuss; S Jiménez-Jorge; I Daviaud; R Guiomar; J O'Donnell; G Necula; M Głuchowska; A Moren Journal: Euro Surveill Date: 2014-02-13
Authors: H Keipp Talbot; Marie R Griffin; Qingxia Chen; Yuwei Zhu; John V Williams; Kathryn M Edwards Journal: J Infect Dis Date: 2011-01-10 Impact factor: 5.226
Authors: Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Karin M Green; James Potts; Anita M Leporati; Jenny Aurielle B Babon; James E Evans; Francis A Ennis; Masanori Terajima Journal: Vaccine Date: 2008-10-31 Impact factor: 3.641
Authors: Brendan Flannery; Swathi N Thaker; Jessie Clippard; Arnold S Monto; Suzanne E Ohmit; Richard K Zimmerman; Mary Patricia Nowalk; Manjusha Gaglani; Michael L Jackson; Lisa A Jackson; Edward A Belongia; Huong Q McLean; LaShondra Berman; Angie Foust; Wendy Sessions; Sarah Spencer; Alicia M Fry Journal: MMWR Morb Mortal Wkly Rep Date: 2014-02-21 Impact factor: 17.586
Authors: Benjamin J Cowling; Wey Wen Lim; Ranawaka A P M Perera; Vicky J Fang; Gabriel M Leung; J S Malik Peiris; Eric J Tchetgen Tchetgen Journal: Clin Infect Dis Date: 2019-05-02 Impact factor: 9.079
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Benjamin J Cowling; Ranawaka A P M Perera; Sophie A Valkenburg; Nancy H L Leung; A Danielle Iuliano; Yat Hung Tam; Jennifer H F Wong; Vicky J Fang; Athena P Y Li; Hau Chi So; Dennis K M Ip; Eduardo Azziz-Baumgartner; Alicia M Fry; Min Z Levine; Shivaprakash Gangappa; Suryaprakash Sambhara; Ian G Barr; Danuta M Skowronski; J S Malik Peiris; Mark G Thompson Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079
Authors: Aurora Signorazzi; Jeroen L A Pennings; Marilena P Etna; Malou Noya; Eliana M Coccia; Anke Huckriede Journal: Vaccines (Basel) Date: 2021-06-17